Johnson & Johnson
This article was originally published in The Gray Sheet
Executive Summary
Firm's Cordis subsidiary currently has no plans to submit a PMA supplement for elective stenting with its Mini Crown coronary stent system, as was earlier being considered by the company ("The Gray Sheet" April 26, p. 7). The device, available in diameters of 2.25-3.25 mm, is approved for treatment of abrupt or threatened closure in patients with failed interventional therapy in native coronary lesions. Approval of 2.5 mm versions of competing stents from Guidant (Duet) and Boston Scientific (Nir) also is limited to abrupt or threatened closure, although 3.0 mm and larger versions of those devices are approved for broader indications for first-line therapy
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.